BioStock: First impressions from Alligator’s new CEO

In June 2021, Søren Bregenholt began his new role as CEO for Lund-based company Alligator Bioscience. The company is about to initiate a phase II trial with mitazalimab, and drug candidate ATOR-1017 is soon to follow. Other projects are also advancing, and BioStock had the opportunity to talk to Bregenholt about his first impressions and what he expects to achieve as CEO of Alligator. 

Read the full interview with Alligator Bioscience's CEO Søren Bregenholt at biostock.se:

https://www.biostock.se/2021/07/first-impressions-from-alligators-new-ceo/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/